Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 19 of 19 matching drugs for PSMB8 — including drugs targeting any of its 8 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
carfilzomib PSMB8 Direct yes 1
ixazomib PSMB8 Direct yes 0
ixazomib citrate PSMB8 Direct yes 0
bortezomib PSMB5 SSL via PSMB5 2
bryostatin 1, paclitaxel CASP8 SSL via CASP8 2
avastin, bortezomib PSMB5 SSL via PSMB5 1
bortezomib, carboplatin, paclitaxel PSMB5 SSL via PSMB5 1
bortezomib, gemcitabine hydrochloride PSMB5 SSL via PSMB5 1
bortezomib, irinotecan PSMB5 SSL via PSMB5 1
bortezomib, radiation therapy PSMB5 SSL via PSMB5 1
bortezomib, temozolomide, pharmacological study PSMB5 SSL via PSMB5 1
carfilzomib PSMB5 SSL via PSMB5 yes 1
cetuximab, bortezomib PSMB5 SSL via PSMB5 1
paclitaxel, bryostatin 1 CASP8 SSL via CASP8 1
tamoxifen citrate, bortezomib PSMB5 SSL via PSMB5 1
vorinostat, bortezomib, pharmacological study, laboratory biomarker analysis PSMB5 SSL via PSMB5 1
vorinostat, therapeutic conventional surgery, bortezomib PSMB5 SSL via PSMB5 1
ixazomib PSMB5 SSL via PSMB5 yes 0
ixazomib citrate PSMB5 SSL via PSMB5 yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.